http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022357324-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba3f70d4bcad1958ae8868ddab079b8f |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70517 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56972 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
filingDate | 2020-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06cf35ef403619bf348b3517bce4d931 |
publicationDate | 2022-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2022357324-A1 |
titleOfInvention | Tcr-independent molecular identification of mutation-related and tumor-specific t cells |
abstract | The present invention relates to the field of tumor immunology. It provides a method for identifying mutation-related human CD8+ T cells, in particular, tumor-specific T cells of a human subject, comprising analyzing CD8+ T cells of the subject by analysing the expression of at least one marker selected from a first group consisting of CD82, CD194, CD244, CD28, CD62L and CD55, and preferably, a marker selected from a second group comprising CD11a or CD18 or CD43. A preferred marker for mutation-related CD8+ T cells is CD82, which may be analysed in combination, e.g., with CD11a. Without the need to identify any epitope to which T cells reacts, this method can advantageously be used to isolate the entire individual pool of mutation-related T cells, and, optionally, to identify the sequence of a mutation-related TCR, which allows for generation of transgenic T cells expressing the TCR. Compositions substantially comprising tumor-specific CD82hiCD8+ T cells and/or CD194hi, CD244−, CD28+, CD62L+ and/or CD55+ CD82hi CD8+ T cells can be used for treatment of a cancer patient, e.g., by adoptive T cell transfer. The method of the invention can also be used for diagnostic purposes to identify human mutation-related T cells or diagnosing a tumor disease or for testing responses of a cancer patient to an immune stimulatory therapy, preferably, a therapy with a checkpoint inhibitor. |
priorityDate | 2019-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 271.